A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is trying to see if talquetamab can help people with a type of cancer called multiple myeloma that has come back or not responded to treatment. They want to figure out the right amount to use in the next stage of the study.
This study is trying to see if talquetamab can help people with a type of cancer called multiple myeloma that has come back or not responded to treatment. They want to figure out the right amount to use in the next stage of the study.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
